Airway Therapeutics Closes $50 Million Equity Round to Advance Late-Stage Development of Zelpultide Alfa
ATLANTA, Aug. 25, 2026 /PRNewswire/ — Airway Therapeutics, Inc., a late-stage clinical biopharmaceutical company developing novel biologic therapies for respiratory, inflammatory, and infectious diseases, today announced the closing of a $50 million
